Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Oral solid lipid nanoparticle-based antitubercular chemotherapy.

Rajesh Pandey1, Sadhna Sharma, G K Khuller

  • 1Department of Biochemistry, Postgraduate Institute of Medical Education & Research, Chandigarh 160 012, India.

Tuberculosis (Edinburgh, Scotland)
|November 1, 2005
PubMed
Summary

Oral solid lipid nanoparticles (SLNs) loaded with tuberculosis drugs significantly reduced dosing frequency. This novel drug delivery system offers a promising approach for improved tuberculosis management and patient compliance.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Transcriptional landscapes of dengue patients reveal associations between HERV activity and disease severity.

NAR molecular medicine·2026
Same author

Intracellular microbial shifts during COVID-19 infection and longitudinal recovery revealed by single-cell RNA sequencing.

iScience·2026
Same author

Comparative GWAS using global and Indian Reference Panels reveals non-coding drivers of COVID-19 severity and mortality.

PLoS neglected tropical diseases·2026
Same author

Remdesivir-bisPropionate, a better derivative of remdesivir against SARS-CoV-2: Comparison of in vitro and in vivo PK/PD Study as well as its therapeutic potential.

PloS one·2026
Same author

Phloretin-induced modulation in gut microbiome, mitigates colonic inflammation and alleviates colitis-associated colorectal cancer in mice.

Computational and structural biotechnology journal·2026
Same author

Functional dynamics between resident transcriptionally active microbes (TAMs) and host genes underlie Dengue severity.

PLoS neglected tropical diseases·2025

Area of Science:

  • Pharmaceutical Nanotechnology
  • Infectious Disease Research
  • Drug Delivery Systems

Background:

  • Tuberculosis (TB) treatment requires prolonged administration of multiple drugs.
  • Poor patient compliance due to frequent dosing is a major challenge in TB therapy.
  • Developing advanced drug delivery systems can enhance therapeutic efficacy and patient adherence.

Purpose of the Study:

  • To evaluate the chemotherapeutic efficacy of oral solid lipid nanoparticles (SLNs) carrying rifampicin, isoniazid, and pyrazinamide against experimental tuberculosis.
  • To assess the pharmacokinetic profile and therapeutic benefit of drug-loaded SLNs compared to free drugs.
  • To determine the potential of SLNs in reducing dosing frequency for tuberculosis treatment.

Main Methods:

  • Solid lipid nanoparticles (SLNs) were prepared using the emulsion solvent diffusion technique.

Related Experiment Videos

  • Encapsulation efficiency of rifampicin, isoniazid, and pyrazinamide within SLNs was determined.
  • Pharmacokinetic studies were conducted in mice following single oral administration of SLNs and free drugs.
  • Therapeutic efficacy was assessed in Mycobacterium tuberculosis H37Rv infected mice by comparing the effect of drug-loaded SLNs and free drugs on bacterial load.

    • Main Results:

    • SLNs achieved encapsulation efficiencies of 51% (rifampicin), 45% (isoniazid), and 41% (pyrazinamide).
    • Therapeutic drug concentrations persisted in plasma for 8 days and in organs for 10 days post-administration of SLNs, significantly longer than free drugs (1-2 days).
    • A single dose of 5 SLN administrations (every 10 days) eradicated tubercle bacilli in mice, whereas 46 daily doses of free drugs were needed for similar efficacy.

    Conclusions:

    • Oral SLNs incorporating first-line anti-TB drugs offer sustained drug release and prolonged therapeutic drug concentrations.
    • This SLN-based formulation drastically reduces dosing frequency, suggesting improved patient compliance.
    • SLN-based antitubercular drug therapy presents a viable strategy for more effective tuberculosis management.